Support Us

Meet the Team
Behind TumorSelect®

Decades of experience. One shared vision: to transform cancer treatment with precision and hope.

Learn More »

At Cloaked Therapeutics, our strength lies in the expertise of our team. With more than 100 years of combined experience in drug discovery, development, and delivery systems, our leadership blends deep scientific knowledge with proven innovation. Each member brings a track record of advancing breakthrough therapies from concept to clinic — and together, we are committed to redefining the future of cancer care.

James D. McChesney

CSO and Founder

James D. McChesney, Ph.D. has more than 50 years of experience in natural products chemistry and more than 25 years of experience in drug discovery and development. He established the National Center for Natural Products Research at Ole Miss, developed a commercial process for paclitaxel production, and created TPI 287, now in Phase II trials.

Steve J. Bannister

Founding Member

Steve J Bannister, PhD has more than 30 years of experience in physical and analytical chemistry for drug delivery systems. Specializes in the design, development, and characterization of drug delivery technologies.

Lisa McChesney-Harris

President and Managing Partner

Lisa McChesney-Harris, PhD has over 32 years of experience in drug development, from preformulation to FDA interactions. Extensive experience with A/NDA submissions and compliance with regulatory requirements.

Our Mission

To use our proprietary LDL technology to create new chemotherapeutics that selectively target tumors and thereby improve tolerability and efficacy of known molecules as well as enable novel ones.

Our Vision

To transform cancer treatment by providing a targeted, effective, and patient-friendly solution. TumorSelect is designed to save lives by selectively attacking cancer cells while preserving healthy tissue, reducing the debilitating side effects of traditional therapies.